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ABSTRACT 
 
Amongst 200 patients developing HAP outwith the ICU, 61% were treated empirically 
without broad-spectrum gram-negative coverage, with clinical cure in 69.7%. Lower disease 
severity markers(SIRS, hypoxia, tachypnoea, neutrophilia) and absence of diabetes mellitus 
and prior doxycycline treatment (but not time to HAP onset) identified patients not requiring 
broad-spectrum gram-negative coverage. 
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 3 
INTRODUCTION 
 
Hospital-acquired pneumonia (HAP) occurring outwith the intensive care unit (ICU) is a 
relatively under-studied nosocomial infection (non-ICU HAP). Gram-negative bacilli (GNB) 
such as Enterobacteriaceae and Pseudomonas aeruginosa are considered canonical HAP 
pathogens and international guidelines recommend empiric broad-spectrum gram-negative 
antimicrobial coverage[1, 2]. However, much of the literature actually describes ventilator-
associated pneumonia (VAP) or ICU-HAP. Case ascertainment bias exists in other studies, 
reporting only on patients able to expectorate sputum or with positive sputum cultures, 
whereas real-life data demonstrate sputum samples are infrequently available and often 
culture-negative[3-6]. Therefore, our understanding of the microbial aetiology of non-ICU 
HAP is incomplete and empiric broad-spectrum gram-negative coverage may not be 
mandated in all cases. In the U.K., doxycycline is widely recommended for empiric treatment 
of low-severity HAP, but we are aware of no clinical data supporting this practice[7]. 
Doxycycline lacks activity against Enterobacteriaceae, P. aeruginosa and Acinetobacter 
baumanii, thus its usage provides an opportunity to address the unanswered question of the 
requirement for broad-spectrum gram-negative coverage in non-ICU HAP. The aims of this 
study were to (i) identify and characterise a representative cohort of patients with non-ICU 
HAP, and (ii) report treatment outcomes without broad-spectrum gram-negative coverage. 
 
METHODS 
 
Case ascertainment 
An electronic search identified all inpatient ward chest x-rays (CXR) performed in two tertiary 
care hospitals in Edinburgh, U.K. over thirteen months (June 2018–July 2019) where the 
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request or report included the terms “consolidation” or “pneumonia” (n=4250). These reports 
were reviewed to identify cases with radiological evidence of infective consolidation (n=728). 
The electronic patient records (EPR) for these patients were reviewed to determine if the 
case definition was met. Non-ICU HAP was defined as (i) new/progressive CXR 
consolidation occurring 48 hours after hospital admission, (ii) in a non-intubated adult (iii) 
in a non-ICU ward and 48h since ICU discharge (ICU defined as capable of providing 
mechanical ventilation), (iv) with documentation of consistent symptoms (cough, sputum, 
pleuritic chest pain, dyspnoea) or chest auscultation findings (crackles, reduced air entry, 
bronchial breathing), and (v) a clinical diagnosis of pneumonia. Patients were excluded if 
pneumonia occurred following a frank aspiration event or a clinical diagnosis of aspiration 
pneumonia was made. 
 
Data collection 
Relevant clinical, laboratory and microbiological details for the first HAP episode were 
recorded from the EPR. Clinical cure was defined as treatment of HAP without requirement 
for antimicrobial escalation and without mortality attributable to HAP (treatment failure refers 
to occurrence of one or both outcomes). Mortality was considered attributable to HAP if 
pneumonia was recorded on the death certificate. 
 
Statistical analysis 
Continuous variables were compared using an unpaired t-test if normally distributed or Mann 
Whitney test if not. Categorical variables were compared using Fisher’s exact test. Following 
receiver operator characteristic analysis, Youden’s J statistic was calculated to determine 
cut-offs for the association between continuous variables and outcome. Variables identified 
by univariate analysis were included in multiple logistic regression after assessing 
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 5 
multicollinearity. Two-tailed p-values are reported and p<0.05 was considered statistically 
significant. Statistical analysis was performed using Prism, version 8.0 (GraphPad Software 
Inc. San Diego, CA). 
 
Ethical approval 
A favourable ethical opinion was provided by the West of Scotland Research Ethics Service 
(19/WS/0152) and Caldicott approval was provided by NHS Lothian R&D (2019/0242). 
 
RESULTS 
 
Characteristics of patients developing non-ICU HAP 
Two hundred patients with non-ICU HAP were identified (Table). Patients had a median age 
of 77 years and 43% were aged 80. A median of two (IQR 1–3) medical co-morbidities 
were present per patient, most commonly chronic lung disease (78%). 57.5% of patients had 
been hospitalised during the preceding year (median 1 prior admission, IQR 0–2). Common 
admission events preceding HAP included receipt of antimicrobials (53.5%) and surgery 
(34%). MRSA carriage was identified in 4/132 screens performed. 11.5% of patients were 
colonised with other antimicrobial-resistant organisms (vancomycin-resistant enterococci, 
n=7; multidrug resistant GNB in urine, n=15; carbapenemase-producing organism, n=1). 
 
Clinical and microbiological features of non-ICU HAP 
HAP was diagnosed a median of 9 days after admission. Sepsis (qSOFA 2 [8]), was 
present in 9.5% of patients and systemic inflammatory response syndrome (SIRS, 2 
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criteria) in 51%. Hypoxia necessitating new or increased supplemental oxygen was common 
(64.5%) but extra-pulmonary organ dysfunction was less common, indicated by low 
requirement for intravenous fluid resuscitation (19%) and low incidence of altered mentation 
(20.5%) and acute kidney injury (12%). The median white cell count was in the normal range 
(10.6 x109/L) but the median CRP was elevated (94 mg/L) and lymphopenia was common 
(70%). Microbiological evaluation consisted of a sputum sample in 18.5% of patients, 
respiratory pathogen PCR throat swab in 27% and blood cultures in 47.5%. It was not known 
if samples were obtained prior to antimicrobials. Pathogenic bacteria were identified in 19/37 
sputum samples and respiratory viruses in 18/54 swabs (Supplementary Table 1). One 
patient had E. coli bacteraemia (1/95 blood cultures). Twelve patients had microbiological 
evidence of HAP caused by Enterobacteriaceae or P. aeruginosa. This was associated with 
number of co-morbidities (median 3 vs. 2, p=0.035) and specifically COPD (58.3% vs. 
23.4%, p=0.013) but not with time to HAP onset, prior hospitalisation or prior antimicrobials. 
 
Management and outcomes 
The most common first-line empiric antimicrobial used was doxycycline (59.5%), followed by 
amoxicillin and gentamicin (14%), vancomycin and gentamicin (6.5%) then piperacillin-
tazobactam (5.5%; Supplementary Table 2). Antimicrobial escalation was required in 18% of 
cases, most commonly from doxycycline to a regimen including broader gram-negative 
coverage (29/36 instances). The median total duration of antimicrobials was 7 days (IQR 5–
7). 
 
Clinical cure was achieved in 70%. Mortality attributable to HAP occurred in 16% of patients. 
Logistic regression identified new/increased supplemental oxygen requirement (OR 5.5, 95% 
CI 2.4–13.9, p=0.0002) and urea >5.5mmol/L (OR 4.6, 95% CI 1.9–12.9, p=0.002) as being 
associated with treatment failure. Undergoing surgery prior to developing HAP was 
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 7 
associated with reduced likelihood of treatment failure (OR 0.4, 95% CI 0.2–1.0, p=0.04). A 
further episode of HAP during the same admission occurred in 16.5% and there were two 
cases of Clostridioides difficile infection following HAP treatment. HAP diagnosis was 
recorded on discharge documentation for coding in 42.5% of cases. 
 
Patients treated without empiric broad-spectrum gram-negative coverage 
61% of patients were treated without empiric broad-spectrum gram-negative coverage, with 
clinical cure in 69.7%. These patients had a lower SIRS score compared to patients treated 
empirically with such coverage (median 1 vs. 2, p<0.0001) consistent with institutional 
antimicrobial guidelines recommending amoxicillin and gentamicin for HAP with 2 SIRS 
criteria or doxycycline for patients with <2. There was no difference in time to HAP onset or 
qSOFA score between the groups. Empiric therapy constituted doxycycline (95.9%), 
amoxicillin (2.5%) or amoxicillin plus clarithromycin (1.6%). In all 29 instances of 
antimicrobial escalation this represented changing to a regimen with broader gram-negative 
coverage.  
 
Logistic regression identified new/increased supplemental oxygen requirement (OR 10.9, 
95% CI 3.1–51.1, p=0.0007), prior doxycycline treatment (OR 8.2, 95% CI 1.3–73.6, 
p=0.03), diabetes mellitus (OR 7.5, 95% CI 2.1–33.1, p=0.004), neutrophil count >6.2x109/L 
(OR 3.9, 95% CI 1.1–16.3, p=0.04) and respiratory rate >18/minute (OR 3.5, 95% CI 1.2–
11.6, p=0.03) as being associated with treatment failure in patients treated without empiric 
broad-spectrum gram-negative coverage.  
 
  
D
ow
nloaded from
 https://academ
ic.oup.com
/cid/article-abstract/doi/10.1093/cid/ciaa391/5817567 by The U
niversity of Edinburgh user on 16 April 2020
Ac
ce
pte
d M
an
us
cri
pt
 
 8 
DISCUSSION 
 
In this cohort, patients with non-ICU HAP were elderly, had significant co-morbidities and the 
overall severity of illness was low. Importantly, a large sub-group were treated successfully 
without broad-spectrum gram-negative coverage. 
 
Representative case ascertainment is challenging for non-ICU HAP[9]. A strength of this 
study was patient identification through systematic screening of inpatient CXRs and 
correlation with clinical data. Relying on submission of sputum cultures, positive sputum 
cultures or discharge coding would have failed to identify most patients. The lack of a control 
group with low-severity HAP treated without antimicrobials is a limitation. 
 
42.5% of all patients had clinical cure without broad-spectrum gram-negative coverage, 
representing 69.7% of patients treated empirically without such coverage. Amongst patients 
treated without such coverage, treatment failure was associated with diabetes, prior 
doxycycline treatment during the same admission, new/increased oxygen requirement, 
neutrophil count and respiratory rate. Hypoxia, tachypnoea and neutrophilia likely relate to 
disease severity. Diabetes has been associated with increased pharyngeal colonisation by 
GNB and therefore could be a risk factor for GNB HAP[10]. Similarly, prior doxycycline 
treatment could deplete the respiratory tract of doxycycline-susceptible organisms, 
influencing the aetiology of subsequent HAP. Importantly, time from admission to HAP onset 
was not associated with treatment failure without broad-spectrum gram-negative coverage. 
Five days of hospital admission is often used as a cut-off to define ‘late-onset’ HAP and risk 
of hospital-acquired GNB infection, based on ICU studies and expert opinion[1, 2]. Amongst 
patients in this cohort with clinical cure without broad-spectrum gram-negative coverage, the 
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 9 
median onset of HAP was 10 days after admission (IQR 5–21), suggesting the currently 
recommended 5-day cut-off is not applicable to non-ICU HAP. 
 
In conclusion, using a representative cohort of patients with non-ICU HAP, we report that a 
large sub-group of patients do not require broad-spectrum gram-negative coverage. Lower 
disease severity markers (SIRS, hypoxia, tachypnoea, neutrophilia) and absence of diabetes 
mellitus and prior doxycycline treatment (but not time to HAP onset) identify this sub-group. 
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TABLE 
Table: Clinical, laboratory and outcome data for included patients with non-ICU hospital-
acquired pneumonia (n=200) 
Variable N (%) 
Patient characteristics  
Age, median (IQR) years 77 (62–87) 
Male 110 (55) 
Co-morbidities  
Chronic lung disease 78 (39) 
Ischaemic heart disease or heart failure 74 (37) 
Cerebrovascular disease 57 (28.5) 
Diabetes mellitus 49 (24.5) 
Chronic kidney disease 46 (23)a 
Solid cancer 45 (22.5) 
Immunosuppressionb 19 (9.5) 
Liver cirrhosis 15 (7.5) 
Haematological malignancy 10 (5) 
Current smoker 35 (17.5) 
Time to onset of HAP, median (IQR) days 9 (5–21) 
Admitting speciality  
Medicine (59.5) 
Surgery (40.5) 
Admission events preceding HAP  
Prior antimicrobials 107 (53.5) 
Surgery 68 (34) 
Other infection 66 (33) 
Endotracheal intubationc 50 (25) 
Bone fracture 38 (19) 
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Intensive care unit admission 30 (15) 
Community-acquired LRTI or pneumonia 42 (21) 
HAP episoded  
Physiological parameters  
Sepsis (qSOFA 2) 19 (9.5) 
SIRS (SIRS 2) 102 (51) 
New/increased supplemental O2 requirement 129 (64.5) 
Altered mentation 41 (20.5) 
Temperature 38.0C or <36C 80 (40) 
Heart rate, mean (SD) beats/minute 95 (22) 
Systolic blood pressure, median (IQR) mmHg 119 (107–132) 
Respiratory rate, median (IQR) breaths/minute 20 (17–24) 
Intravenous fluid resuscitation  38 (19) 
ICU admission 9 (4.5) 
Laboratory parameters  
New acute kidney injurye 24 (12) 
Total white cell count, x109 L-1, median (IQR) 10.6 (7.7–14.7) 
Neutrophil count, x109 L-1, median (IQR) 8.4 (5.7–11.8) 
Lymphocyte count, x109 L-1, median (IQR) 1.0 (0.7–1.6) 
C-reactive protein, mg L-1, median (IQR) 94 (38–190) 
Outcomes  
Clinical cure 140 (70) 
HAP antimicrobial escalation 36 (18) 
Mortality attributable to HAP 32 (16) 
Further episode of HAP 33 (16.5) 
a requiring haemodialysis in 5 cases 
b therapeutic immunosuppression (n=13), anti-neoplastic chemotherapy (n=3), HIV infection (n=2), 
IgG2 & 3 deficiency (n=1). 
c for general anaesthesia or mechanical ventilation. 
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d physiological and laboratory parameters obtained within 24 hours of HAP diagnosis were recorded  
e increase in creatinine of 26.5 mol/L from last measurement. 
IQR: interquartile range; LRTI: lower respiratory tract infection; SIRS: systemic inflammatory response 
syndrome; SD: standard deviation; ICU: intensive care unit 
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